Nippon Shinyaku (4516.T)

Executive Summary

Nippon Shinyaku is a research-driven Japanese pharmaceutical company with a century-long history, specializing in innovative therapeutics for rare diseases. Its lead product, viltolarsen (Viltepso), is approved in Japan and the U.S. for Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping, and the company continues to expand its neuromuscular pipeline with next-generation antisense oligonucleotides targeting other DMD mutations. Beyond DMD, Nippon Shinyaku is advancing a Phase 2 candidate for pulmonary arterial hypertension (NS-863) and a Phase 2 program for eosinophilic granulomatosis with polyangiitis (NS-229), leveraging its proprietary nucleic acid and small molecule platforms. With a dual-market strategy focused on Japan and global expansion, the company commands a market cap of approximately $1.7 billion and has 11 commercial products, underscoring its established commercial footprint.

Upcoming Catalysts (preview)

• Q3 2026NS-229 Phase 2 top-line data for eosinophilic granulomatosis with polyangiitis (EGPA)60% success
• Q4 2026NS-089/NCNP-02 Phase 2 data for DMD exon 44 skipping55% success
• Q3 2026NS-863 Phase 2 trial initiation for pulmonary arterial hypertension90% success